Renatus Tactical Acquisition Corp I Announces Closing of Upsized $241.5 Million Initial Public Offering
CORAL GABLES, Fla.--(BUSINESS WIRE)--Renatus Tactical Acquisition Corp I (Nasdaq: RTACU) (the 'Company') today announced the closing of its upsized initial public offering of 24,150,000 units at $10.00 per unit, including 3,150,000 units issued pursuant to the full exercise of the underwriters' over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $241,500,000.
The units began trading on The Nasdaq Global Market ('Nasdaq') under the ticker symbol 'RTACU' on May 15, 2025. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols 'RTAC' and 'RTACW,' respectively.
'We are very pleased with the strong market reception to our offering and grateful for the trust placed in us by our investors. As we move forward, we see this as an opportunity to help shape the SPAC product to be more market friendly for potential targets and accessible to retail shareholders,' said Eric Swider, Chief Executive Officer, Renatus Tactical Acquisition Corp I. 'With our upsized offering now complete, we look forward to evaluating compelling opportunities in our target sectors, with a focus on innovative companies at the intersection of blockchain technology and data security, to identify an investment that we believe can deliver meaningful shareholder value.'
The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any industry, sector or geographic region, the Company intends to focus its search on high potential businesses based in the United States in the cryptocurrency and blockchain, data security and dual use technologies markets.
Clear Street acted as sole book-running manager for the offering. Paul Hastings LLP served as legal counsel to the Company.
A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on May 14, 2025. The offering was made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained from Clear Street, Attn: Syndicate Department, 150 Greenwich Street, 45th floor, New York, NY 10007, by email at ecm@clearstreet.io, or from the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that constitute 'forward-looking statements,' including with respect to the anticipated use of the net proceeds from the offering and the Company's expectations regarding its ability to complete an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the Company will ultimately complete a business combination transaction in the sector it is targeting or at all. Management has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While they believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond management's control. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement on Form S-1 and preliminary prospectus for the Company's offering filed with the U.S. Securities and Exchange Commission (the 'SEC'). Copies of these documents are available on the SEC's website, at www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
5 Major Social Security Mistakes Boomers Can't Stop Making
Retirement planning is both complicated and high-stakes — a recipe for mistakes with major financial consequences. And sure enough, Business Insider reported that more than half of Americans over 65 earn less than $30,000 a year. As you plan your own retirement, watch out for these Social Security mistakes plaguing current baby boomers. Check Out: Read Next: Too many people reach their early 60s and think: 'I've been paying into the system for decades, I need to lock in my share!' Unfortunately, that leaves them with far lower lifetime benefits than if they'd waited. 'Filing early means locking in a permanent reduction in benefits, up to 30% if your full retirement age is 67,' explained Christine M. Parisi, senior wealth advisor at R.W. Rogé & Company. If you take benefits at age 62, you receive just 70% of your full retirement benefit. At 67, you collect 100%. Wait until 70, and you receive 124% of your full Social Security benefit. Learn More: Plan to continue working for a while? Hold off on taking Social Security — and not just to secure higher benefits. 'If your earnings exceed the annual limit, the Social Security Administration may withhold $1 in benefits for every $2 you earn over the threshold,' Parisi added. 'Benefits can also push your income higher for Medicare-related costs like IRMAA, meaning you could end up paying more in premiums.' Plus, combining your salary with Social Security can push you into a higher tax bracket. You can end up handing much of that money right back to Uncle Sam. If one spouse earned significantly higher income, or worked for many years longer, their benefits will be higher. Plan to optimize those, perhaps by having that spouse delay benefits while the family lives on earned income or distributions from retirement accounts before taking benefits. Parisi noted that different rules apply to surviving spouses. 'If your late spouse worked long enough to qualify for Social Security, you may be able to start collecting survivor benefits as early as age 60. Unfortunately, many don't realize this is even an option until it's too late.' First and foremost, when you planned your retirement income, did you account for taxes? You'll still owe income taxes in retirement, at least under current tax laws. 'A portion of Social Security benefits are taxable, up to 85%, based on your provisional income,' said Keith Hensley of Florida Financial Planning. Many states tax Social Security benefits as well. The upshot? You may need more money saved for retirement than you thought. Again, you may be better off working another year and delaying Social Security benefits. It may not be too late for a Roth conversion to make sense. If you have a year with lower income, consider taking the tax hit and converting some of your traditional retirement funds to Roth accounts, so they can compound tax-free and you can avoid paying taxes on withdrawals in retirement. If Social Security is your only — or your primary — plan for retirement income, expect stormy seas ahead. William Connor, CFA and CFP with Sax Wealth Advisors, added some historical context. 'Social Security was created as a safety net for older Americans. It was not designed as a primary source of retirement income, and won't replace your working income.' Instead, combine it with other sources of income such as retirement accounts, health savings accounts (HSAs), taxable brokerage accounts, real estate investments and perhaps part-time fun working gigs. The less you rely on Social Security income, the more comfortable and secure your retirement will be. More From GOBankingRates 3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025 8 Common Mistakes Retirees Make With Their Social Security Checks How Much Money Is Needed To Be Considered Middle Class in Every State? This article originally appeared on 5 Major Social Security Mistakes Boomers Can't Stop Making Sign in to access your portfolio
Business Wire
26 minutes ago
- Business Wire
Alnylam Receives European Commission Approval for AMVUTTRA ® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA ® (vutrisiran). The approval broadens the indication for AMVUTTRA, which now becomes the first and only RNAi therapeutic approved by the EC for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of hereditary transthyretin-mediated amyloidosis (hATTR) in adults. Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy Share 'Estimates show approximately 100,000 people are affected by ATTR amyloidosis across Europe, most with cardiomyopathy, so this approval marks a critical step toward addressing this underserved patient population,' said Pushkal Garg, M.D., Chief Medical Officer at Alnylam. 'AMVUTTRA is supported by a well-established efficacy and safety profile, with over 6,000 patient-years of global experience in the treatment of hATTR with polyneuropathy. By delivering rapid and sustained knockdown of TTR through convenient, quarterly dosing, it offers a clinically differentiated approach with the potential to transform outcomes for patients living with this debilitating and potentially fatal disease. We now look forward to securing access to AMVUTTRA for eligible patients across the EU as quickly as possible.' The EC decision is based on positive results from the pivotal HELIOS-B Phase 3 study – a randomized, double-blind, placebo-controlled, multicenter, global trial that enrolled a diverse group of patients reflective of the contemporary ATTR-CM population, including those receiving substantial concurrent use of available standard-of-care therapies such as tafamidis and SGLT2 inhibitors. AMVUTTRA met all 10 pre-specified primary and secondary endpoints across both the overall and monotherapy populations. These included statistically significant reductions in all-cause mortality and recurrent cardiovascular events, as well as significant improvements in functional capacity (6-minute walk test), health status and quality of life (Kansas City Cardiomyopathy Questionnaire), and heart failure symptoms and severity (NYHA class). In the overall population, AMVUTTRA achieved a 28% reduction in the primary composite of all-cause mortality and recurrent cardiovascular events as compared to placebo. Mortality in this population was significantly reduced by 36% through 42 months in a pre-specified secondary endpoint analysis which included up to 36 months of the double-blind period plus six months of open-label extension. In HELIOS-B, rates of adverse events (AEs), serious AEs, severe AEs and AEs leading to study drug discontinuation were similar between the AMVUTTRA and placebo arms. Adverse drug reactions of AMVUTTRA include injection site reactions and increase in blood alkaline phosphatase and alanine transaminase. Detailed results from the HELIOS-B study were published in The New England Journal of Medicine. 1 'The HELIOS-B findings provide compelling evidence to support the use of vutrisiran as a first-line treatment option for patients with ATTR-CM,' said Marianna Fontana, M.D., Ph.D., HELIOS-B investigator, Professor of Cardiology, University College London, National Amyloidosis Center, Royal Free Hospital, London. 'As a physician, it is a privilege to see the true impact on patients in the clinic. The trial enrolled a broad population reflective of real-world clinical practice, and that's what makes the results so meaningful. This is a milestone for patients, who now have a new treatment option that has the potential to significantly improve outcomes of this disease.' ATTR-CM is caused by the deposition of misfolded TTR fibrils, which drive progressive and irreversible cardiovascular damage and premature death. AMVUTTRA is an RNAi therapeutic that works upstream by delivering sustained knockdown of disease-causing TTR at its source. In the EU, it is administered as a subcutaneous injection once every three months, either by a healthcare professional, or self-administered by patients or their caregivers, offering flexibility in treatment delivery. 'Amyloidosis is a serious and progressive disease that significantly impacts not only patients' physical health, but also their quality of life and independence. I am thrilled by the news of a new therapy for people in the EU living with ATTR-CM who often face delayed diagnosis. Having a new treatment option available marks a welcome development for the amyloidosis community,' said Giovanni d'Alessio, President of the Amyloidosis Alliance. In May 2025, the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on the maintenance of the EU Orphan Designation for AMVUTTRA in ATTR amyloidosis. AMVUTTRA was approved in March 2025 by the U.S. Food and Drug Administration (FDA) and the Brazilian Health Regulatory Agency (ANVISA) for the treatment of the cardiomyopathy of wild-type or hereditary ATTR amyloidosis in adults. Alnylam continues to pursue additional global submissions to bring vutrisiran to patients worldwide. Indications In the EU, AMVUTTRA ® (vutrisiran) is indicated for the treatment of: hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN). wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Important Safety Information Reduced Serum Vitamin A Levels and Recommended Supplementation Vutrisiran treatment leads to a decrease in serum vitamin A levels. Supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients taking vutrisiran. Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness). Adverse Reactions Commonly reported adverse reactions with vutrisiran were injection site reactions and increase in blood alkaline phosphatase and alanine transaminase. For additional information about vutrisiran, please see the full Summary of Product Characteristics. About AMVUTTRA ® (vutrisiran) AMVUTTRA ® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of variant and wild‑type transthyretin (TTR), addressing the underlying cause of transthyretin (ATTR) amyloidosis. Administered quarterly via subcutaneous injection, vutrisiran is approved and marketed in more than 15 countries for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. It is also approved in the U.S. and Brazil for the treatment of wild-type or hereditary ATTR amyloidosis in adult patients with cardiomyopathy (ATTR-CM). In the EU, AMVUTTRA is administered once every three months, either by a healthcare professional or through self-administration by patients or their caregivers. About ATTR Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating and fatal disease caused by misfolded transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant and affects approximately 50,000 people worldwide, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant and impacts an estimated 200,000-300,000 people worldwide. 2-5 About RNAi RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. 6 Its discovery has been heralded as 'a major scientific breakthrough that happens once every decade or so,' and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. 7 By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors that encode for disease-causing or disease pathway proteins – thus preventing them from being made. 6 This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its ' Alnylam P 5 x25 ' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. Alnylam Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam's expectations, beliefs, goals, plans or prospects including, without limitation, Alnylam's expectations regarding the safety and efficacy of AMVUTTRA for the treatment of ATTR-CM; the potential for AMVUTTRA to be used as a first-line treatment for ATTR-CM; the potential for AMVUTTRA to address the underserved ATTR-CM patient population and to improve outcomes for ATTR-CM patients; and Alnylam's ability to secure access to AMVUTTRA for eligible patients across the EU and the timing of such access should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam's ability to successfully execute on its ' Alnylam P 5 x25 ' strategy; Alnylam's ability to successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam's product candidates; actions or advice of regulatory agencies and Alnylam's ability to obtain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam's approved products globally; and any delays, interruptions or failures in the manufacture and supply of Alnylam's product candidates or its marketed products; as well as those risks more fully discussed in the 'Risk Factors' filed with Alnylam's 2024 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam's subsequent Quarterly Reports on Form 10-Q and in its other SEC filings. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
Yahoo
29 minutes ago
- Yahoo
Got $1,000? Super Micro Computer Stock Is a Brilliant Backdoor AI Play
Super Micro Computer's DLC technology offers huge cost savings for companies constructing data centers. Supermicro faces some headwinds due to tariffs. Supermico's stock looks cheap compared to many other AI players. 10 stocks we like better than Super Micro Computer › There are many ways to play the AI investment trend. Hardware companies like Nvidia (NASDAQ: NVDA) are powering the training of AI models, suppliers like Taiwan Semiconductor (NYSE: TSM) are building the chips for Nvidia, and software companies like Palantir (NASDAQ: PLTR) are providing platforms to deploy AI for real-world use. I tend to prefer neutral options in the AI space. That way, I can benefit from the general buildout of AI rather than having one company succeed. While Nvidia is an excellent choice in this realm, so is Super Micro Computer (NASDAQ: SMCI). Super Micro Computer, often called Supermicro, builds server racks and cooling solutions for data centers to house high-powered computing devices like Nvidia's GPUs. Supermicro has seen impressive growth over the past few years, but what's ahead could make investors even more money. Server racks are fairly commoditized, so there isn't much to separate one competitor from another. However, one area where a company can make a name for itself is customizability and cooling technology. Supermicro's racks are highly modular, allowing clients of all sizes to find a server rack that fits their workload size and application. Another advantage of Supermicro's solutions is its direct liquid-cooling (DLC) technology. Traditionally, computing hardware is cooled by moving air across the unit, which isn't the most efficient way to cool these units. Supermicro's DLC technology moves liquid across the surface (contained in tubes), which is a far more efficient way to cool them. Furthermore, because these units don't have to account for airflow, Supermicro's clients can pack more server racks into a given space, which helps decrease building costs. Supermicro estimates that this provides up to 40% energy savings and 80% space savings. Supermicro also has key partnerships in the industry, most notably with Nvidia. Nvidia's most powerful chip, based on Blackwell architecture, can be placed in servers purpose-built to hold those exact GPUs, helping users squeeze out every last bit of performance from these chips. In Supermicro's third quarter of fiscal year 2025 (ended March 31), sales rose 19% year over year to $4.6 billion. While that's solid growth, the company faces some headwinds due to tariffs. Supermicro also faces some headwinds moving into next quarter, with revenue expected to be about $6 billion at the midpoint of guidance, indicating 13% growth. However, one area where Supermicro shines is its valuation, as shares can be scooped up for a dirt-cheap level. Supermicro's stock trades for just 15.2 times fiscal year 2026's earnings, which is far cheaper than most of the AI stocks in the market, which commonly trade in the high-20s to the low-30s range. As Supermicro figures out tariffs and shifts supply chains around, it could see its growth start to reaccelerate, as AI demand is still massive. Nvidia forecast, using third-party data, that data center capital expenditures would reach $400 billion in 2024 but could rise to $1 trillion by 2028. Should this occur, Supermicro will see its business rapidly expand due to the field in which it's playing. That kind of growth could send Supermicro's stock soaring if it can capture the bulk of server infrastructure, making Supermicro a potentially fantastic buy to capitalize on the AI arms race that's still heating up. Before you buy stock in Super Micro Computer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Super Micro Computer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Keithen Drury has positions in Nvidia and Taiwan Semiconductor Manufacturing. The Motley Fool has positions in and recommends Nvidia, Palantir Technologies, and Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy. Got $1,000? Super Micro Computer Stock Is a Brilliant Backdoor AI Play was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
